Table 1.
Neuromyelitis optica (NMO)-IgG/AQP4-Ab seropositivity rates as found in an M1-AQP4-DNA-based cell-based assay with leaky scanning (LS, ‘assay A’) and in an M23-AQP4-DNA-based cell-based assay (’assay B’)
| NMO-IgG/AQP4-Ab a | |
|---|---|
| Positive |
|
| Either assay A or B |
77/368 (20.9%) |
| Assay A |
76/368 (20.7%) |
| Assay B |
74/368 (20.1%) |
| Both assay A and B |
73/77 (94.8%) |
| Assay A only |
3/77 (3.9%) |
| Assay B only |
1/77 (1.3%) |
| Negative | |
| Neither assay A nor B | 291/368 (79.1%) |
aM1-DNA- and M23-DNA-transfected cells were tested simultaneously on separate biochips within the same well to ensure identical incubation conditions.